Sign in
or
Register
0
Add listing
View all results
No results
News
Events
The industry
arrow_drop_down
Industry overview
Industrial biotech
Swiss Biotech Report
Success Stories
Company directory
Jobs
Networking platforms
Newsletter
Association
arrow_drop_down
Mission and services
Members
Academy
Partners
Team
Media
Add listing
Abicipar (mono-DARPin anti-VEGF)
Product
prev
next
Leave a review
Claim listing
Bookmark
Share
Report
prev
next
Indicaton
Wet Age-related Macular Degeneration (wetAMD)
Therapeutic indications
Ophthalmology
Type of product
Other
Company
Molecular Partners AG
Table
Phase
Filing
Partnering status
Partnered
Partner
Allergan / abbVie
Available in
globally
You may also be interested in
TOP-N53, TOP-V122, TOP-M119 and TOP-N44
TOPADUR has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases as chronic wounds, glaucoma, colorectal cancer, hair loss and skin aging.
Phase I started
TOP-N53, TOP-N44, TOP-M119, TOP-V122, TOP-T5
preclin. development for diabetic foot ulcer, burn wounds, normal tension glaucoma, hair growth and chemotherapy induced hair loss, prevention of colorectal cancer, Elimination of cancer stem cells and skin aging
Phase I started
TOTIPHARMACEUTICAL
Polypharmacology for all therapeutic aeras using nano-drug delivery systems
Discovery
Cart
×
View all results
No results
Facebook
Twitter
WhatsApp
Telegram
Pinterest
LinkedIn
Tumblr
VKontakte
Mail
Copy link
This site uses cookies:
Find out more.
Accept